A Billion-Dollar Bet on AI-First Drug Development

Despite the emergence of new modalities and drug development technologies, the cost and time to produce new therapies has changed little, and failure rates remain high. Xaira aims to change that with a systematic, AI‑driven approach that tackles three pervasive bottlenecks—choosing the right targets, designing the right molecules, and matching the right patients—by running as much work as possible in silico and using high‑dimensional causal datasets to train “virtual cell” foundation models. The company is initially focusing on high‑value, historically undruggable targets and ultimately on building a pipeline of differentiated biologics. We spoke with Marc Tessier‑Lavigne, co‑founder and CEO of Xaira, about applying end‑to‑end AI across target discovery, molecular design, and patient stratification; the company’s more than $1 billion in funding, and how it seeks to enable a new generation of scientists fluent in both AI and biology.

You can listen to A Billion-Dollar Bet on AI-First Drug Development online on Radio and Podcast. Open the player on this page to stream the available audio.

A Billion-Dollar Bet on AI-First Drug Development is an episode from The Bio Report by Levine Media Group.

This episode is 46:31 long.

This episode was published on Jan 28, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from The Bio Report when more episodes are available from the podcast feed.